IAM · Iambic Therapeutics, Inc.
$16.34
-7.47 (-31.37%)
At close · Oct 19
Return incl. dividend (before tax)
Market Cap
$823.35M
Shares
47.40M
Volume · Oct 19
2.39M
Avg daily vol (3 sessions)
2.46M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.34
Open$21.00
Day$14.10–21.54
Available close range$16.34–23.81
Avg vol available · 3d2.5M
Short vol53%
DataOct 2026–Oct 2026
The closing range uses available history since Oct 15, 2026; less than a full year is stored.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Limited
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
52-week position
0%
near low
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$11.5M over 90 days · 0% sells
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
643%
annualized · 1-yr
Max drawdown
−31%
past year
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
52-week position
0%
Bearish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$11.5M over 90 days · 0% sells
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its available closing range
Range low $16
Now $16 · 0%
Range high $24
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IAM
this stock
Iambic Therapeutics, Inc.
|
$823.35M | — | — | — | — |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.73B | +10.7% | +46.2% | 29.4 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.41B | +1.3% | +20.8% | 19.6 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Smart Money
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 16, 2026
- This year
- 3
Iambic Therapeutics filed an amended and restated certificate of incorporation with Delaware and adopted amended and restated bylaws on October 16, 2026 in connection with completing its IPO.
ViewEarnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IAM | — | — | — | — | — |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | — | — | — | — | — |